Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

The Value of a Coordinated Care Team

January 12th 2024

Highlights the advantages of various providers working together for patient care.

The Benefits of Multidisciplinary Care in Prostate Cancer Management

January 12th 2024

Panel discusses how collaboration between specialties improves patient outcomes.

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

January 12th 2024

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

January 11th 2024

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Dr Bilusic on the Use of PARP Inhibitors in Prostate Cancer

January 10th 2024

Marijo Bilusic, MD, PhD, discusses key considerations and unanswered questions regarding the use of PARP inhibitors in patients with prostate cancer.

Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC

January 5th 2024

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

A Drive to Help Patients Launches a Career in Revolutionizing Prostate Cancer Care

December 29th 2023

Howard I. Scher, MD, took a passion for improving cancer care and patient outcomes in prostate cancer and turned it into an extraordinary and explosive field of clinical research.

Metastatic Prostate Cancer: Background and Patient Prognosis

December 20th 2023

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

December 20th 2023

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Optimizing Care of Patients With Advanced Prostate Cancer: Introduction

December 19th 2023

Brief background on prostate cancer and overview of the program.

Lutetium Lu 177 Vipivotide Tetraxetan Addresses Unmet Need in Taxane-Naive mCRPC

December 18th 2023

Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.

TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?

December 18th 2023

Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

December 18th 2023

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

December 18th 2023

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression

December 15th 2023

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Evolving Paradigms in the Detection and Treatment of Prostate Cancer

December 15th 2023

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

December 8th 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Novel Combination Regimens Are Expanding the Prostate Cancer Treatment Paradigm

December 1st 2023

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Dr Wise on the Importance of Genetic Testing in mCRPC

November 30th 2023

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

FDA Approves Enzalutamide for nmCSPC With High-Risk Biochemical Recurrence

November 17th 2023

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.